Νανοι ατρικη : Νεο τερεσ Εξελι ξεισ ςτη Δια γνωςη και Θεραπει α τησ Αθηρωμα τωςησ

Transcript

1 Νανοι ατρικη : Νεο τερεσ Εξελι ξεισ ςτη Δια γνωςη και Θεραπει α τησ Αθηρωμα τωςησ τζργιος Λογοθετίδης Καθηγητη σ Τμη ματοσ Φυςικη σ, Διευθυντη σ Εργαςτηρι ου Νανοτεχνολογι ασ LTFN

2 Outline Nanotechnology Nanotechnology in Medicine: Nanomedicine Nanoparticles in Atherosclerosis Diagnosis and Treatment Nanotechnology enabled Stents LTFN R&D activities in Nanomedicine Conclusions 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 2

3 Nanotechnology (- ies) m (1-100nm) Nanotechnology: Nature Made BBs Man Made Fle a Hair μm Red Blood cells 2-5 μm Bacteria ~1 μm Virus DNA 0.5-2nm The Universal Compound Silicon dioxide (silica) is one of the most commonly encountered substances in both daily life and in electronics manufacturing. Crystalline silicon dioxide (in several forms: quartz, cristobalite, tridymite) is an important constituent of a great many minerals and gemstones, both in pure form and mixed with related oxides. Beach sand is mostly silica. The working of silica into glass (usually by the addition of natron -- sodium oxide -- to lower the melting point) has been known since antiquity, with polished glass lenses in eyeglasses and optical instruments dating back more than 5 centuries. The whole of planar electronics processing and the modern IC industry has been made possible by the unique properties of silicon dioxide: the only native oxide of a common semiconductor which is stable in water and at elevated temperatures, an excellent electrical insulator, a mask to common diffusing species, and capable of forming a nearly perfect electrical interface with its substrate. Deposited silicon dioxide, almost always by CVD approaches, is almost as old as thermal growth on the substrate, and has been employed in various ways in IC fabrication due to its familiarity, versatility, and reliability. Let us examine this interesting material. SiO2 is formed by strong, directional covalent bonds, and has a well-defined local structure: four oxygen atoms are arrayed at the corners of a tetrahedron around a central silicon atom: [The oxygen atoms are electronegative, and some of the silicon valence electron density is transferred to the oxygen neighbors, but it is incorrect to regard the material as a salt of a Si[+4] ion with O[-2] ions, as is sometimes seen in the literature: the directionality of the bonds is essential to the observed structures. ] The bond angles around O-Si-O are essentially the tetrahedral angle, 109 degrees; the Si-O distance is 1.61 A (0.16 nm) with very little variation. [The bond distance is slightly smaller than the sum of the conventional covalent "radii" of the atoms: Si (0.11 nm) + O(0.066 nm) = 0.18 nm. Thus we ought to show the atoms as slightly penetrating each other; the sphere size was shrunk in the diagram above for clarity.] 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 3

4 Νanο-Bio-Ιnfo Technologies... MACRO 10-1 Structure Dimension (m) Physics Convergence.of Basic Sciences & Meet Engineering- Info- Pharma- Medicine Radical Improvement of Quality of Life. MICRO ΝΑΝΟ 10-4 Biology Cells 10-7 Chemistry Electronics Molecular Biology Micro-Electronics Molecular Chemistry Material Structures Quantum Effects Biochips Sensors Micro & Nano- Devices Nano- Electronics Regenerative Medicine Drug-delivery devices. Convergence Physical Laws Biological Principles Chemical Properties & Form Complex Systems (Nano- Bio- Info- Chemical) Year 4

5 Nanotechnology Approaches & Tools Top-down (Photolithography, Microcontact printing) techniques begin with a macroscopic material or group of materials and incorporate smaller-scale details into them. Top-down Approach Bottom-up (Organic-synthesis, Selfassembly) approaches, begin by designing and synthesizing custommade molecules with the ability to self-assemble or self-organize into higher order mesoscale and macroscale structures. Bottom-up approach J.V. Barth, G.Costantini and K. Kern, Nature 437, (2005) 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 5

6 Medicine- Biology & Nanotechnology Therapy (drug delivery) Diagnosis Drug discovery Biomimetism Monitoring / detection New Biomaterials Implantable Devices Self Assembly Nanotechnology meets Biology Biosensors Nanomaterials Biochips Nanotools In Vivo Systems Bioanalytics Therapeutic devices Molecular electronics Smart materials Integrated devices Applications 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 6

7 Nanomedicine: A new Concept Nanomedicine The convergence Nanotechnology with modern Biology and Medicine, The Science & Technology of: Diagnosing - Treating Disease, and Improving Human Health, using Molecular tools & Molecular knowledge of the human body. Nanoparticles for Treatment of Disease Nanoparticles would deliver treatment to specificaly targeted sites, including places that drugs do not easily. For example, gold nanoshells that were targeted to tumors might, when hit by infrared light, heat up enough to destroy the growths. Implants with Superior Durability & Biocompatiblity Nanometer - scale modifications of implant surfaces would improve implant durability and biocompatibility. For instance, an artificial hip coated with nanoparticles might bond to the surrounding tone more tightly than usual, thus avoiding loosening. Improved Imaging for early diagnosis Improved or new contrast agents would detect problems at earliest, more treatable stages. They might reveal tumors [red] only a few cells in size. 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 7

8 Nanoparticles in NanoMedicine Nanomedicine presents revolutionary opportunities in the fight against many Diseases. Interactions with Tissue environment are events occurring at the Nanoscale. NP Engineering affords a fertile landscape for controlled application (e.g., for Drug- & Gene- Delivery, Probing DNA Structures), Using NPs such as : Liposomes Polymer NPs (Nanospheres, Nanocapsules) Solid Lipid NPs, Nanocrystals Dendrimers Fullerenes Inorganic NPs (Gold & Magnetic) and Quantum Dots 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 8

9 Nanoparticles in NanoMedicine. Biomedical Nanotechnology presents revolutionary opportunities in the fight against many Diseases.such as Cancer, Diabetes, Cardiovascular, Neurodegenerative & Inflammatory/Infectious diseases, Diseases of blood & lungs, Orthopaedic problems, etc Can be applied by using: Various NPs & Dendrites between 2-50nm 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 9

10 Nanotechnology in Regenerative Medicine Approach of Tissue Engineering & Nanotechnology Biomimetic Materials, Cells, Bioactive Factors...lead to Clinical Applications in Regenerative Medicine The Design, Specification & Fabrication of cells, Biomaterials, or Biomolecules to Restore or Modify the Biological Function of Tissues. 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 10

11 Nanomedicine for CVD Cardiovascular Disease (CVD) is leading cause of death globally with 30% of all deaths Worldwide 17 Million people die each Year from CVD! Underling Mechanism of CVD is Atherosclerosis Need for Accurate Diagnosis & Effective Treatment by Nanomedicine 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 11

12 Pathophysiology of Atherosclerosis Atherosclerosis is induced by low-grade Inflammatory process in the Vascular Wall, leading to formation of Atherosclerotic Plaque The Term Atherosclerosis is derived from: Athero the soft lipid rich material in centre of atheroma & Sclerosis (scarring) to connective tissue in plaques. Complexicity of Atherosclerosis Intimal surface of RCA from a 32-year-old man With heart attack V. Karagkiozaki, et al, Nanomedicine Highlights in Atherosclerosis: A Review, J. Nanoparticle Res. 2013, 15: ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 12

13 NPs for Atherosclerosis V. Karagkiozaki, Nanomedicine Highlights in Atherosclerosis: A Review, J. Nanoparticle Res. 15:1529, ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 13

14 Nanotheranostic Strategies for CVD Advantages of NPs Certain contrast agents and potent drugs may exhibit a poor blood half-life and high systemic toxicity, which can potentially be improved by encapsulation within NPs NPs can increase the effectiveness of diagnostic / therapeutic agents Decorating NPs with targeting molecules against biomarkers of a disease facilitates their specific delivery and accumulation within pathological tissue Nanoparticles that hold both therapeutic drugs and diagnostic labels are popularly referred to as theranostic nanoparticles Tang J, et al. Curr Cardiovasc Imaging Rep. 2012; 5(1): ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 14

15 Clinical Practice for CVD Treatment: PTCA with Stents In Angioplasty an expanding Balloon inserted into the Artery to Compress the plaque & Widen the passageway A Stent is mounted on the Ballon Catheter The Ballon is inflated & the Stent is expanded The Ballon is removed & the Stent is implanted in the Arteria The result is improved Blood Flow to the Heart 1 st Bare Metal Stents/ nd Drug Eluting Stents-DES/ ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 15

16 Drug Eluting Stents - DES Polymers of DES may cause: Inflammation of Vessel Wall & Delayed Endothelialization Platelet Aggregation & Late Stent Thrombosis State-of-the-art in DES Coatings Bioabsorbable Polymers PLLA, PLA, PLGA etc No Polymers Textured Surface Nano Technology Surface Modifications Nano membranous Filters Photolithographic Etching V. Karagkiozaki, S.Logothetidis, Novel nanostructured biomaterials: Implications for Stent Thrombosis. Int. J. Nanomed. 7, 6063 (2012) 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 16

17 CONTROVERSIES FOR DES LTFN Experiments.. Surface Characterization of Stents by SEM & AFM S. Kassavetis, S.Logothetidis et al Expansion Effect on the Coated Coronary Stent Surface & NanomechanicalProperties MRS Fall Meeting 2008, U.S.A. 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 17

18 Nanotechnology:The Future of Stenting? Ballon A. Past Present Future Bare Metal Stent More Efficacious than Ballon A. Metal DES More Efficacious than BMS no drug drug NANOTECHNOLOGY?? 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 18

19 Nanotechnology Approaches for DES Νanotechnology: Offers the Potential of Engineering Biomaterials that Mimick the Nanostructure of Vascular Tissues & Enhance Endothelialization Targets to make the Surface of Stents highly Nanoporous for DES applications NanoStent with NPs Σi Nanostructure of Vascular Tissue MIV combines a Nanoporous HAp with lipidbased Drug-delivery technologies into a Polymer-free Drug-delivery system SEM typical patterns of nanostructures at metal stent V. Karagkiozaki, S. Logothetidis, A. Pappa, Nanomedicine approaches for mastering Atherosclerosis: A Review, J. Biomed. Nanotech. In press, ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 19

20 Nanotechnology Lab LTFN Nanotechnology Lab LTFN at Aristotle University of Thessaloniki Founded by Prof. S. Logothetidis in 1991 LTFN Research & Technologies: Organic Electronics Thin Films & Nanoengineering Nanomedicine & Nanobiotechnology Nanometrology & Optical Technology LTFN 2006 Razor Blades LTFN 2009 Lenses & Cutting Tools Packaging LTFN 2012 Stents & Implants 35 New Sientists (Physicists, Chemists,Engineers Biologists, Medicine, Material Scientist) 5 Technicians & Support ~2000 m 2 of Lab Space 70 Affiliated Labs 100 Affiliated Researchers OTFTs OPVs Biosensors LTFN 1998 LTFN 2004 LTFN 2006 LTFN LTFN 2012 LTFN ο LTFN Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 20

21 LTFN Research Facilities Synthesis & Fabrication Facilities Spin Coating Vacuum Electrospinning Facilities Technologies Nanomedicine & Cell Culture Facility Optical Technology & Nanometrology Contact Angle SNOM RAMAN AFM 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 21

22 LTFN R&D Activities: Current National Projects Objectives Nanoscaffolds made of Biodegradable Polymer (Polycaprolactone-PCL) for Tissue Regeneration Scaffolds loaded with biodegradable PLGA NPs as Drug carriers of Fluorescent Curcumin NPs of 150nm Biodegradable PLGA NPs with the anti- Oxidant, anti- Inflammatory, Fluorescent Drug (Curcumin) Nanoparticulate Scaffold Bare PCL Scaffold Nanomedicine for Advanced, Bioactive / -mimetic Materials for Cardiovascular Implants (NANOCARDIO) Manufacturing of advanced Bioinspired Materials with controlled surface properties for Cardiovascular Implants Multifunctionality High local drug concentration Controlled release 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ

23 LTFN R&D Activities: Current National Projects Nanomaterials with bioactive agents for cartilage regeneration cartilage and treatment of Osteoarthritis (NanoArthroChondros) Production of implants from biomaterials that regenerate tissue for various clinical applications Objectives Develop Cartilage regeneration in the knee joint Generation of Nano-Biomimetic Scaffolds Functionalized with Bioactive Molecules Provision of Stem Cells to ensure the attraction & the proliferation of chondrocytes Study of Protein-cellular interactions at Nanoscale SEM Chitosan:Gelatin (75:25) Thin Film AFM Chitosan:Gelatin (75:25) Thin Film Collaboration with 2 Greek Companies 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ

24 Development of Biodegradable Polymeric Nanoplatform for Drug Delivery 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 24

25 Development of Drug Eluting Platform for DES A wide range of Materials & Fabrication Methods have been used to manufacture Stent coatings Limitations come from Biodegradability & Slow Degradation rates that may cause Inflammation, Thrombosis & Implant Failure Our goal is to Design & Develop: BP Matrices in a Multi-layer Architecture, with Tailored Properties & Diversity of Nanopores for Controlled Drug loading and release at the Diseases site BP Scaffolds embedded with Drug-loaded BP NPs for controlled Drug Loading & Release BP Scaffolds loaded with Drug in the Fibers for sustained Drug Release. 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 25

26 Drug Delivery Nanoplatform for DES: Materials & Architectures Materials: BP, PLGA at various lactic & glycolic ratios Drugs: e.g. Dipyridamole (DPM): Antiplatelet & Vasodilation Effect Architectures: PLGA 1 Substrate Dexamethasone (DEX): Anti-inflammatory Properties Single Layers & Multi-layers BP Substrate PLGA 1 BP Substrate PVA PLGA 2 PLGA 1 BP Substrate Drug Drug PLGA 2 PLGA 1 BP Substrate Single Layer blends (PLGA 1 & BP) PLGA:BPType A Substrate PLGA:BP Type B Substrate PLGA:BP Type C Substrate 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 26

27 Nanoporous Materials PLGA were atomically smooth with Rrms < 1nm M-layers Pores varied in Diameter ( nm) & in Depth (10-50nm) M-layers Pore Density is ~ pores/μm 2 Atomic Force Microscopy- AFM Imaging PLGA 1 BP PLGA 1 BP PLGA 2 PLGA 1 BP V. Karagkiozaki, E. Vavoulidis, S. Logothetidis, Int J Nanomedicine. 2012; 7: ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 27

28 Monitoring Film Properties Thickness & Pores: SE Evaluation of the Optical Properties of the Drug: Dipyridamole-DPM The SE data analysis using the EM Theory provides valuable results for Drug & Geometrical structure of the Platform PLGA 2 (69%) + DPM (31%) 134nm PLGA 1 BP 32nm 42nm Substrate 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 28

29 Monitoring Drug Loading: In-situ & Real-time SE PLGA 2+DRUG/PLGA 1/BP < > EXP < > FIT (PLGA 1 + DPM)/PLGA 2/PCL/c-Si < > EXP < > FIT Drug ,0 1,5 2,0 2,5 3,0 3,5 4,0 4,5 5,0 5,5 6,0 6,5 7,0 Photon Energy (ev) SE data reveals the homogeneity of the Drug loading samples The Drug has a uniform distribution within the layer, because of the homogeneous pores distribution in PLGA layer 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ PLGA 1 BP Substrate

30 Drug Release Kinetics of Dipyridamole-DPM PLGA 2 + DPM PLGA 1 BP PLGA 2+ DPM (3:1) Top layer PLGA 2 PLGA 2+ DPM (3:1) Medium layer PLGA 1 +DPM BP 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 30

31 Development & Validation of Multifunctional Nanoparticles 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 31

32 Intensity (%) Fabrication of Polymeric Nanoparticles FITC-labeled Polymeric hydrophilic Coating SEM Imaging Fluorescent antiinflammatory Drug 200 nm PLGA hydrophobic core AFM Imaging Targeting ligands Fabrication Method: Nanoprecipitation Organic phase Aqueous phase is NPs are dispersed in dropped in the organic the aqueous phase DLS Measurements Size: 156 ±0,5nm Z-potential: +21 ±2mV PDI< ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ Particle Size (nm) 32

33 Development of BP Scaffolds for Drug Delivery 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 33

34 Development of Nanoscaffolds for DES Nanoscaffolds: Made of the BP Polycaprolactone PCL Embedded with PLGA NPs as Drug carriers PCL Scaffolds with Anti-inflammatory Drug loaded within the Fibers Selection of Materials: PCL is FDA approved PCL is degraded by hydrolysis of its ester linkages in physiological conditions Usage for long term implantable devices, owing to its slow degradation PLGA NPs loaded with Anti-oxidant/-inflammatory Fluorescent Drug PLGA A naturally occurring Poly-phenolic compound, Curcumin Cationic polymer Drug With Anti-inflammatory & anti-oxidant effects 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 34

35 Development of Nanoparticulate Scaffolds A. PCL Nanofibrous Scaffolds via ESD Electrostatic Spray Deposition (ESD) SEM images AFM images 20 μm B. Drug loaded PLGA Nanoparticles Nanoprecipitation Organic phase Aqueous phase is NPs are dispersed in dropped in the organic the aqueous phase 200 nm DLS Measurements Size: 151 ±0,5nm Z-potential: ±2,3nm PDI<0.2 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 35

36 O 2 Plasma treated scaffolds Morphology No treatment 20 W 40 W 20W Oxygen Plasma Treatment did not induce significant changes in the morphology of the Fibers 40W Oxygen Plasma Treatment induced disentanglement in the Polymer Chains Surface Chemistry XPS spectra higher peaks at O- related binding energies and lower peaks at C-C related ones indicating the succesful crosslinking of plasma and the increase in O related groups 36

37 Nanoparticle embedded scaffolds Therapeutic NPs AFM Bare PCL Scaffold Nanoparticulate Scaffold SEM AFM Cross sections 2 μm 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 37

38 Drug release from NPs into Scaffolds NPs from Plasma Treated Scaffolds exhibit a more sustained Drug Release Plasma Treatment reduces the degree of Burst Drug Release Both systems follow more or less the same Release Kinetics Plasma Treated ones don t reach a Plateau till the 4 th Week 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ

39 Fabrication of Drug - loaded PCL Nanoscaffolds ESD applied to develop Drug loaded Scaffolds. Optimization led to Bead-free Nanofibers Blend PCL- Drug 1 % w/w Blend PCL- Drug 3 % w/w Formation of Beads along the Fibers Formation of Bead-free Fibers Multimodal distribution of Fiber diameter was observed with diameters in the range of nm The incorporation of the Drug did not change the Morphology of the PCL Fibers 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 39

40 Release of the Drug from NPs & loaded PCL Nanofibers Release from NPs Release from Nanofibers Comparative Diagram NPs Blend PCL- Drug 3 % w/w Burst release from the PLGA NPs & 70% of the Drug Released in the 5 th day Slower & More Sustained Drug Release of the PCL Nanofibers compared to PLGA NPs. 60% of the Drug released in the 3 rd Week. The first 4 days the Release exhibited a Slow rate. 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 40

41 Summary & Future Perspectives Nanotheranostics for the effective Treatment of Atherosclerosis is the Direction Nanotechnolgy Applications in Stents involve the development of Biomimetic, Nanoscaffolds, BP Nanoparticles and their combination with Dual Role: for Drug Delivery & Tissue Engineering Development of Biodegradable Polymeric Platform for Drug Elusion composed either of Nanoporous Multi-layers or of NPs Embedded into BP Scaffolds for better Tissue Integration A Strategy to control Drug Release based on the diversity of Polymers with different degradation rates, the architecture of Drug Vehicles (NPs, Scaffolds, or Nanoporous Materials) 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 41

42 Events in Nanomedicine & Nanotechnology NN 11 Years of International Conference on Nanosciences & Nanotechnologies ISSON 8 Years of International Summer Schools on N&N, Organic Electronics & Nanomedicine ISFOE 7 Years of International Symposium on Flexible Organic Electronics EXPO 4 Years of NANOTEXNOLOGY EXPO 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 42 42

43 Website: 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 43

44 ΕΤΧΑΡΙΣΩ ΠΟΛΤ ΓΙΑ ΣΗΝ ΠΡΟΟΧΗ Α! τζργιος Λογοθετίδης 13ο Βορειοελλαδικο Καρδιολογικο Συνζδρειο, 2014, Θεςςαλονι κη, Ελλα δα/ Στζργιοσ Λογοθετι δησ 44